ArticleStructural heart : the journal of the Heart Team2025
Clinical Impact of Prosthesis Oversizing in Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement.
Article in Structural heart : the journal of the Heart Team, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Among patients undergoing transcatheter aortic valve replacement (TAVR), valve sizing is essential to guarantee procedural success and long-term durability of transcatheter heart valves (THVs). The optimal sizing strategy for self-expanding (SE) intra-annular THVs remains unclear. The aim of this study is to evaluate the impact of prosthesis oversizing on procedural and clinical outcomes in patients undergoing TAVR with the Portico and Navitor THVs. Methods: This retrospective, multicenter study included patients who underwent TAVR with SE intra-annular THVs between October 2017 and September 2024. Patients were stratified by the median oversizing value (14%) into low- (≤14%) and high- (>14%) oversizing groups. The primary endpoint was technical success. Secondary outcomes included 30-day device success, permanent pacemaker implantation, cardiovascular mortality, heart failure-related hospitalization, and valve dysfunction at 12 months. Results: A total of 400 patients (mean age 83.0 ± 6.0 years; 65.8% female) were included. Technical success was higher in the low-oversizing group (96.7 vs. 92.1%; Conclusions: In patients undergoing TAVR with SE intra-annular THVs, low-oversizing (≤14%) was associated with higher technical success and fewer valve-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.